{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T04:36:18Z","timestamp":1777869378455,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Innere Medizin"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s00108-026-02105-5","type":"journal-article","created":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T19:33:29Z","timestamp":1775158409000},"page":"515-523","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Vaskulitiden und Anti-GBM-Erkrankung","Vasculitides and anti-GBM disease"],"prefix":"10.1007","volume":"67","author":[{"given":"Adrian","family":"Schreiber","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonas","family":"Reimers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,4,2]]},"reference":[{"key":"2105_CR1","doi-asserted-by":"crossref","unstructured":"Almaani S, Fussner LA, Brodsky S et\u00a0al. (2021) ANCA-Associated Vasculitis: An Update. J\u00a0Clin Med 10","DOI":"10.3390\/jcm10071446"},{"key":"2105_CR2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/s41584-023-00958-w","volume":"19","author":"G Emmi","year":"2023","unstructured":"Emmi\u00a0G, Bettiol\u00a0A, Gelain\u00a0E et\u00a0al (2023) Evidence-Based Guideline for the diagnosis and management of eosinophilic granulomatosis with polyangiitis. Nature Reviews Rheumatology 19:378\u2013393","journal-title":"Nature Reviews Rheumatology"},{"key":"2105_CR3","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1136\/annrheumdis-2017-211897","volume":"77","author":"G Emmi","year":"2018","unstructured":"Emmi\u00a0G, Rossi\u00a0GM, Urban\u00a0ML et\u00a0al (2018) Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis 77:952\u2013954","journal-title":"Ann Rheum Dis"},{"key":"2105_CR4","doi-asserted-by":"publisher","first-page":"S71","DOI":"10.1016\/j.kint.2023.10.008","volume":"105","author":"J Floege","year":"2024","unstructured":"Floege\u00a0J, Jayne\u00a0DRW, Sanders\u00a0JSF et\u00a0al (2024) KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)\u2013Associated Vasculitis. Kidney International 105:S71\u2013S116","journal-title":"Kidney International"},{"key":"2105_CR5","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1136\/ard.2010.137778","volume":"70","author":"O Flossmann","year":"2011","unstructured":"Flossmann\u00a0O, Berden\u00a0A, De Groot\u00a0K et\u00a0al (2011) Long-term patient survival in ANCA-associated vasculitis. Ann Rheum Dis 70:488\u2013494","journal-title":"Ann Rheum Dis"},{"key":"2105_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1136\/ard-2022-223764","volume":"83","author":"B Hellmich","year":"2024","unstructured":"Hellmich\u00a0B, Sanchez-Alamo\u00a0B, Schirmer\u00a0JH et\u00a0al (2024) EULAR recommendations for the management of ANCA-associated vasculitis: 2022 update. Ann Rheum Dis 83:30\u201347","journal-title":"Ann Rheum Dis"},{"key":"2105_CR7","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1016\/j.ekir.2024.12.026","volume":"10","author":"V Ivkovi\u0107","year":"2025","unstructured":"Ivkovi\u0107\u00a0V, Bajema\u00a0I, Bruchfeld\u00a0A et\u00a0al (2025) Efficacy and Safety of Rituximab in Antiglomerular Basement Membrane Disease. Kidney International Reports 10:743\u2013752","journal-title":"Kidney International Reports"},{"key":"2105_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1056\/NEJMoa2023386","volume":"384","author":"DRW Jayne","year":"2021","unstructured":"Jayne\u00a0DRW, Merkel\u00a0PA, Schall\u00a0TJ et\u00a0al (2021) Avacopan for the Treatment of ANCA-Associated Vasculitis. N\u00a0Engl J Med 384:599\u2013609","journal-title":"N Engl J Med"},{"key":"2105_CR9","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10157-013-0869-6","volume":"17","author":"JC Jennette","year":"2013","unstructured":"Jennette\u00a0JC (2013) Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol 17:603\u2013606","journal-title":"Clin Exp Nephrol"},{"key":"2105_CR10","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa0909169","volume":"363","author":"R Jones","year":"2010","unstructured":"Jones\u00a0R, Cohen Tervaert\u00a0J, Hauser\u00a0T et\u00a0al (2010) Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis. New England Journal of Medicine 363:211\u2013220","journal-title":"New England Journal of Medicine"},{"key":"2105_CR11","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0204-y","volume":"6","author":"AR Kitching","year":"2020","unstructured":"Kitching\u00a0AR, Anders\u00a0HJ, Basu\u00a0N et\u00a0al (2020) ANCA-associated vasculitis. Nat Rev Dis Primers 6:71","journal-title":"Nat Rev Dis Primers"},{"key":"2105_CR12","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/S0140-6736(23)01736-1","volume":"403","author":"A Kronbichler","year":"2024","unstructured":"Kronbichler\u00a0A, Bajema\u00a0IM, Bruchfeld\u00a0A et\u00a0al (2024) Diagnosis and management of ANCA-associated vasculitis. Lancet 403:683\u2013698","journal-title":"Lancet"},{"key":"2105_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2024.103531","volume":"23","author":"H Kuang","year":"2024","unstructured":"Kuang\u00a0H, Jiang\u00a0N, Jia\u00a0XY et\u00a0al (2024) Epidemiology, clinical features, risk factors, and outcomes in anti-glomerular basement membrane disease: A systematic review and meta-analysis. Autoimmunity Reviews 23:103531","journal-title":"Autoimmunity Reviews"},{"key":"2105_CR14","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1053\/j.ajkd.2022.07.006","volume":"81","author":"H Kuang","year":"2023","unstructured":"Kuang\u00a0H, Liu\u00a0J, Jia\u00a0XY et\u00a0al (2023) Autoimmunity in Anti-Glomerular Basement Membrane Disease: A Review of Mechanisms and Prospects for Immunotherapy. Am J Kidney Dis 81:90\u201399","journal-title":"Am J Kidney Dis"},{"key":"2105_CR15","doi-asserted-by":"crossref","unstructured":"Mcadoo SP, Pusey CD (2025) Anti-glomerular basement membrane disease - treatment standard. Nephrol Dial Transplant","DOI":"10.1093\/ndt\/gfaf190"},{"key":"2105_CR16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"BH Rovin","year":"2021","unstructured":"Rovin\u00a0BH, Adler\u00a0SG, Barratt\u00a0J et\u00a0al (2021) KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International 100:S1\u2013S276","journal-title":"Kidney International"},{"key":"2105_CR17","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1016\/S0140-6736(22)00461-5","volume":"399","author":"S Sethi","year":"2022","unstructured":"Sethi\u00a0S, De Vriese\u00a0AS, Fervenza\u00a0FC (2022) Acute glomerulonephritis. Lancet 399:1646\u20131663","journal-title":"Lancet"},{"key":"2105_CR18","doi-asserted-by":"publisher","first-page":"1887","DOI":"10.1681\/ASN.2020101431","volume":"32","author":"CR Shen","year":"2021","unstructured":"Shen\u00a0CR, Jia\u00a0XY, Luo\u00a0W et\u00a0al (2021) Laminin-521 is a Novel Target of Autoantibodies Associated with Lung Hemorrhage in Anti-GBM Disease. J\u00a0Am Soc Nephrol 32:1887\u20131897","journal-title":"J Am Soc Nephrol"},{"key":"2105_CR19","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa0909905","volume":"363","author":"JH Stone","year":"2010","unstructured":"Stone\u00a0JH, Merkel\u00a0PA, Spiera\u00a0R et\u00a0al (2010) Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis. New England Journal of Medicine 363:221\u2013232","journal-title":"New England Journal of Medicine"},{"key":"2105_CR20","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.7326\/ANNALS-24-03947","volume":"178","author":"B Terrier","year":"2025","unstructured":"Terrier\u00a0B, Pugnet\u00a0G, De Moreuil\u00a0C et\u00a0al (2025) Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis. Annals of Internal Medicine 178:1249\u20131257","journal-title":"Annals of Internal Medicine"},{"key":"2105_CR21","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1681\/ASN.2021111460","volume":"33","author":"F Uhlin","year":"2022","unstructured":"Uhlin\u00a0F, Szpirt\u00a0W, Kronbichler\u00a0A et\u00a0al (2022) Endopeptidase Cleavage of Anti-Glomerular Basement Membrane Antibodies in vivo in Severe Kidney Disease: An Open-Label Phase 2a Study. J\u00a0Am Soc Nephrol 33:829\u2013838","journal-title":"J Am Soc Nephrol"},{"key":"2105_CR22","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1056\/NEJMoa1803537","volume":"382","author":"M Walsh","year":"2020","unstructured":"Walsh\u00a0M, Merkel\u00a0PA, Peh\u00a0CA et\u00a0al (2020) Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N\u00a0Engl J Med 382:622\u2013631","journal-title":"N Engl J Med"},{"key":"2105_CR23","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41584-021-00718-8","volume":"18","author":"RA Watts","year":"2022","unstructured":"Watts\u00a0RA, Hatemi\u00a0G, Burns\u00a0JC et\u00a0al (2022) Global epidemiology of vasculitis. Nature Reviews Rheumatology 18:22\u201334","journal-title":"Nature Reviews Rheumatology"},{"key":"2105_CR24","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2311155","volume":"390","author":"ME Wechsler","year":"2024","unstructured":"Wechsler\u00a0ME, Nair\u00a0P, Terrier\u00a0B et\u00a0al (2024) Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. N\u00a0Engl J Med 390:911\u2013921","journal-title":"N Engl J Med"},{"key":"2105_CR25","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","volume":"376","author":"M Wechsler","year":"2017","unstructured":"Wechsler\u00a0M, Akuthota\u00a0P, Jayne\u00a0D et\u00a0al (2017) Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. New England Journal of Medicine 376:1921\u20131932","journal-title":"New England Journal of Medicine"}],"container-title":["Die Innere Medizin"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02105-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00108-026-02105-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-026-02105-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T13:38:03Z","timestamp":1777556283000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00108-026-02105-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,2]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2105"],"URL":"https:\/\/doi.org\/10.1007\/s00108-026-02105-5","relation":{},"ISSN":["2731-7080","2731-7099"],"issn-type":[{"value":"2731-7080","type":"print"},{"value":"2731-7099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,2]]},"assertion":[{"value":"18 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Schreiber und J.\u00a0Reimers geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}